Modus治疗机构获得意大利批准, 扩大慢性肾病患者的血清试验范围。 Modus Therapeutics gets Italian approval to expand sevuparin trial for anemia in chronic kidney disease patients.

由卡罗林斯卡开发公司支持的Modus Therapeutics获得意大利监管机构的批准,开始第二阶段的临床试验,试验塞武与慢性病相关的贫血. Modus Therapeutics, backed by Karolinska Development, has received Italian regulatory approval to begin the second phase of a Phase 2 clinical trial testing sevuparin for anemia linked to chronic kidney disease. 试验将于2025年底启动,将根据初始单剂量阶段的阳性安全结果测试三剂剂量,Sevuparin在最初的单剂量阶段被很好地释放。 The trial, launching in late 2025, will test three doses based on positive safety results from the initial single-dose phase, where sevuparin was well-tolerated. 这一里程碑有助于为医疗需求严重未得到满足的疾病开发潜在的新治疗方法。 This milestone advances the development of a potential new treatment for a condition with significant unmet medical needs.